Gene · 4277
Papers3,381
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
401 to 420 of 3,381
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| KLF4-mediated upregulation of the NKG2D ligand MICA in acute myeloid leukemia: a novel therapeutic target identified by enChIP. | Cell Commun Signal | 2023 | 37143070 | PubTator, text mining | PubMed |
| Breast Cancer Stem Cell-Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands. | Cancer Immunol Res | 2023 | 37139603 | PubTator, text mining | PubMed |
| Copper-binding proteins genes set predicting the overall survival and immune infiltration in hepatocellular carcinoma by bioinformatic analysis. | Biochem Biophys Rep | 2023 | 37125079 | PubTator, text mining | PubMed |
| Wiskott-Aldrich syndrome gene as a prognostic biomarker correlated with immune infiltrates in clear cell renal cell carcinoma. | Front Immunol | 2023 | 37122750 | PubTator, text mining | PubMed |
| Identification of small-molecule protein-protein interaction inhibitors for NKG2D. | Proc Natl Acad Sci U S A | 2023 | 37098070 | PubTator, text mining | PubMed |
| Multiancestry sex-stratified genomic associations with HIV viral load and controller status from the ICGH. | JCI Insight | 2023 | 37097752 | PubTator, text mining | PubMed |
| The Identification and Clinical Value Evaluation of CYCS Related to Asthma through Bioinformatics Analysis and Functional Experiments. | Dis Markers | 2023 | 37091894 | PubTator, text mining | PubMed |
| Epigenetic modulation and prostate cancer: Paving the way for NK cell anti-tumor immunity. | Front Immunol | 2023 | 37090711 | PubTator, text mining | PubMed |
| A close look at current γδ T-cell immunotherapy. | Front Immunol | 2023 | 37063836 | PubTator, text mining | PubMed |
| LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors. | Transl Lung Cancer Res | 2023 | 37057124 | PubTator, text mining | PubMed |
| Editorial: Immune determinants of COVID-19 protection and disease: A focus on asymptomatic COVID and long COVID. | Front Immunol | 2023 | 37056777 | PubTator, text mining | PubMed |
| Doxorubicin-Mediated miR-433 Expression on Exosomes Promotes Bystander Senescence in Multiple Myeloma Cells in a DDR-Independent Manner. | Int J Mol Sci | 2023 | 37047835 | PubTator, text mining | PubMed |
| iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors. | Stem Cell Res Ther | 2023 | 37038186 | PubTator, text mining | PubMed |
| Allograft inflammatory factor 1 is a potential diagnostic, immunological, and prognostic biomarker in pan-cancer. | Aging (Albany NY) | 2023 | 37014322 | PubTator, text mining | PubMed |
| Pan-Cancer analysis and experimental validation identify the oncogenic nature of ESPL1: Potential therapeutic target in colorectal cancer. | Front Immunol | 2023 | 37006282 | PubTator, text mining | PubMed |
| Cellular immunotherapy combined with platinum-based chemotherapy prolongs survival for non-small cell lung cancer patients. | Neoplasma | 2023 | 37005956 | PubTator, text mining | PubMed |
| Exploration of the role of NKG2D ligands MICA and MICB in JAK2 V617F-positive myeloproliferative neoplasms. | HLA | 2023 | 37002719 | PubTator, text mining | PubMed |
| AVPR2 is a potential prognostic biomarker and correlated with immune infiltration in head and neck squamous cell carcinoma. | BMC Med Genomics | 2023 | 36998036 | PubTator, text mining | PubMed |
| Advances in CAR-T Cell Therapy in Head and Neck Squamous Cell Carcinoma. | J Clin Med | 2023 | 36983174 | PubTator, text mining | PubMed |
| The Role of NK Cells in EBV Infection and Related Diseases: Current Understanding and Hints for Novel Therapies. | Cancers (Basel) | 2023 | 36980798 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4277/papers?page=21